Tamoxifen (Nolvadex): The Gold Standard PCT SERM
Last updated: March 2026
Tamoxifen (Nolvadex) is a selective estrogen receptor modulator that blocks estrogen at the pituitary and breast tissue. FDA-approved since 1977 for breast cancer, it became the PCT cornerstone — restoring LH, FSH, and natural testosterone production while preventing gynecomastia during hormonal recovery.
Elimination Time
Per Day Oral
From Baseline
📋 On this page
How Tamoxifen Works
Tamoxifen is a selective estrogen receptor modulator — antagonist in breast and pituitary, partial agonist in bone. This tissue selectivity drives PCT recovery: blocking pituitary estrogen feedback increases gonadotropin release.
Tamoxifen occupies estrogen receptors in the hypothalamus and pituitary, blocking estrogen's suppressive feedback. Without this signal, GnRH pulses increase, driving up LH and FSH secretion. Higher LH stimulates Leydig cells to produce testosterone.
In breast tissue, tamoxifen competitively inhibits estradiol binding, suppressing proliferative effects. This prevents and can reverse gynecomastia — the breast tissue response to elevated estrogen during or after anabolic steroid use.
Unlike its blocking action elsewhere, tamoxifen acts as a partial estrogen agonist in bone, helping preserve bone mineral density. This is a side benefit during PCT — no accelerated bone loss during hormonal transition.
After anabolic suppression, the HPTA is dormant. Tamoxifen's pituitary blockade kick-starts gonadotropin release, driving testicular function recovery. Clinical studies show testosterone can normalize within 4-6 weeks.
What the Clinical Trials Show
Data from breast cancer trials, hypogonadism studies, and male fertility research in peer-reviewed literature.
Dosing Protocols
Common tamoxifen dosing protocols for PCT, gynecomastia prevention, and TRT maintenance.
| Protocol | Dose | Duration | Notes |
|---|---|---|---|
| PCT Standard | 40mg/day → 20mg/day | 4-6 weeks | 40mg weeks 1-2, then 20mg weeks 3-6. Start 2 weeks after last injection. |
| PCT Heavy Cycle | 40mg/day → 20mg/day | 6-8 weeks | Extended protocol for 19-nor compounds or long esters. |
| Gynecomastia Prevention | 10-20mg/day | As needed | Use during cycle if gyno symptoms appear. |
| Gynecomastia Treatment | 20-40mg/day | 3-6 months | For pubertal or existing gyno. Response rate 50-75%. |
| TRT Adjunct | 10mg EOD | Ongoing | Some use low-dose to manage E2 without AI. Monitor lipids. |
| Fertility Protocol | 10-20mg/day | 3+ months | Raises LH/FSH for spermatogenesis while on low-dose TRT. |
Tamoxifen vs Other SERMs
How tamoxifen compares to other SERMs used for PCT and hormone optimization.
Tamoxifen
20-40mg/day. Fewer visual side effects than clomid. Bone-protective.
Clomiphene
25-50mg/day. More visual disturbances, mood issues. Contains zuclomiphene.
Enclomiphene
12.5-25mg/day. Cleanest profile. Not widely available (not FDA-approved).
Raloxifene
60mg/day. Better gyno reduction, weaker LH stimulation. Good combo.
Side Effects & Risks
Drug Interactions
Important drug interactions to be aware of when using tamoxifen.
CYP2D6 Inhibitors (Paroxetine, Fluoxetine, Bupropion)
These antidepressants inhibit CYP2D6, which converts tamoxifen to its active metabolite endoxifen. Can reduce efficacy by 65-75%. Use alternative antidepressants (venlafaxine, sertraline).
Aromatase Inhibitors (Anastrozole, Letrozole)
Controversial combo in PCT. Some stack them; others argue AI reduces the estrogen tamoxifen needs to block. If combining, use AI sparingly and monitor lipids.
Warfarin / Anticoagulants
Tamoxifen can increase anticoagulant effect. Monitor INR closely if on blood thinners. Increased bleeding risk.
HCG
Common PCT combo. HCG stimulates testes directly; tamoxifen restores pituitary signaling. Use HCG for first 2-3 weeks, then continue tamoxifen alone.
Key Studies
Primary research supporting tamoxifen's use in PCT and hormone optimization.
Tamoxifen Effects on Serum Testosterone in Hypogonadal Men
Tamoxifen 20mg/day increased LH by 55% and testosterone by 140% in hypogonadal men over 3 months. FSH also increased significantly.
PMID: 2897875 →EBCTCG Meta-Analysis: Tamoxifen in ER+ Breast Cancer
5 years of tamoxifen reduced breast cancer recurrence by 39% and mortality by 30% in ER+ patients. Foundation for long-term safety data.
PMID: 21703678 →Tamoxifen for Pubertal Gynecomastia
Tamoxifen 10-20mg/day reduced breast volume in 50-75% of adolescent males with pubertal gynecomastia over 6 months.
PMID: 15682325 →Tamoxifen vs Clomiphene in Male Infertility
Both increased testosterone comparably, but tamoxifen had fewer side effects. 65% preferred tamoxifen for tolerability.
PMID: 22612453 →Key Takeaways
- Raises LH ~55% and restores testosterone in 75-85% of men by week 6
- Gold standard PCT drug with 30+ years of clinical data
- Blocks gynecomastia at the breast tissue level
- Standard dose: 40mg/day weeks 1-2, 20mg/day weeks 3-6
- Fewer side effects than clomiphene in most users
- Half-life 5-7 days — once daily dosing works
- Optimal PCT duration for different steroid cycles
- Best tamoxifen + HCG timing and ratios
- Long-term effects of repeated PCT cycles
- Whether combining with AI helps or hurts recovery
🔬 Verified Research Source
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports HighPeptides at no extra cost. All Swiss Chems products include third-party lab testing certificates.
🛒 Recommended Products
Testing supplies and support supplements for PCT.
Related Resources
Research-Grade Peptides
Third-party tested compounds with certificates of analysis. Used by researchers worldwide.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational purposes only. It is not medical advice. Tamoxifen is a prescription medication. Off-label use for PCT is not FDA-approved for this indication. Always consult a qualified physician before starting any hormone therapy. Clinical data cited is from published literature for educational reference.